MS SB2694

Requires health benefit plans entered into or renewed on or after July 1, 2026 to cover biomarker testing for diagnosis, treatment, management, or monitoring when supported by FDA approvals, CMS coverage determinations, or nationally recognized clinical practice guidelines

Mandates insurers provide specific written justification for any denied biomarker testing claims, explaining in detail why coverage was denied for the individual patient

Requires health insurers to update and publicly post medical policies and coverage guidelines by September 1, 2026, with any subsequent changes made public 30 days before taking effect

Authorizes the Department of Insurance to conduct periodic audits to ensure compliance and establishes that prior authorization requests may be submitted by ordering providers, laboratories, or enrollees

Defines biomarker testing broadly to include single-analyte tests, multi-plex panel tests, whole exome/genome/transcriptome sequencing, and other genomic or molecular sequencing of tissue, blood, or other biospecimens